ICRT 14

• Description:

  ICRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT), with IC50 of 40.3 nM against Wnt responsive STF16 luciferase.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• Target:

  Wnt

• Type:

  Reference compound

• Related Pathways:

  Stem Cell/Wnt

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/iCRT-14.html

• Purity:

  99.72

• Solubility:

  DMSO : ≥ 29 mg/mL

• Smiles:

  O=C(S/1)N(C2=CC=CC=C2)C(C1=C\C3=C(C)N(C(C)=C3)C4=CN=CC=C4)=O

• Molecular Formula:

  C21H17N3O2S

• Molecular Weight:

  375.44

• Precautions:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• References & Citations:

  [1]Gonsalves FC, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA. 2011 Apr 12;108 (15) :5954-63.|[2]Bilir B, et al. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 2013 Nov 4;11:280.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [677331-12-3]